TSM5 TSM10 TSM20 99% White powder High Quality semaglutide weight loss
TDS 12 Inquiries
112603-35-7
Pharmaceutical Grade
99%
shanghai
JL
10ml
2027-07-21
Peptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificates
-
TDS
Basic Info-
Product Name:
insulin-like growth factor 1, des-(1-3)-
Other Name:insulin-like growth factor 1, des-(1-3)-;4-70-Insulin-likegrowth factor I (huMan);Insulin-lkie Growth Factor(IGF-1);IGF-1 DES 1mg/2mg
CAS No.:112603-35-7
Molecular Weight:0
Categories:
Research-
Class:
GLP-1R agonist
Status:FDA-approved (Ozempic / Wegovy / Rybelsus)
Mechanism:Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.
Activity note:Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).
Source:Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI
Clinical Development:FDA:Ozempic, Wegovy, Rybelsus (approved 2017-12-05)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
NEJM: Wilding et al. (2021) — STEP-1; NEJM: Marso et al. (2016) — SUSTAIN-6; J Med Chem: Lau et al. (2015) — Discovery of Semaglutide; FDA: Ozempic (NDA 209637)
Disclaimer:Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Peptide
-
Location:
zhejiangshengjinhuashiyiwushijiangdongjiedaodongnanlu656hao
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
5-10
-
Year of Establishment:
2026
-
-
Inquiry History12 Inquiries
Country Product Purchase Quantity Date Posted
China
TSM
1000 Jun 15, 2026
China
Igf-1 DES
50 MG Dec 15, 2025
Russia
igf-1 des 1-3
1 G Apr 22, 2025
Australia
IGF-1 DES
1 MT Feb 28, 2026
France
IGF1 DES
30 MG Jan 27, 2026
United States
Igf-1 DES
1 MT Nov 19, 2025
United States
IGF-1 DES
1 G Oct 11, 2024
United States
IGF1 DES
10 MG Jul 31, 2026
Cyprus
Igf-1 des
150 MG Jul 9, 2026
Netherlands
IGF-1 DES
1200 MG Jun 27, 2026
United States
IGF-DES
20 MG Apr 10, 2026
United States
High Quality IGF-1 DES Peptide Manufacturer 99% Pure
2 MG Oct 9, 2025 Post an enquiry for this product